uniQure N.V. (QURE)
NASDAQ: QURE · Real-Time Price · USD
17.14
-0.25 (-1.44%)
At close: Apr 7, 2026, 4:00 PM EDT
17.70
+0.56 (3.27%)
Pre-market: Apr 8, 2026, 8:02 AM EDT
uniQure Employees
uniQure had 221 employees as of December 31, 2025. The number of employees increased by 12 or 5.74% compared to the previous year.
Employees
221
Change (1Y)
12
Growth (1Y)
5.74%
Revenue / Employee
$72,842
Profits / Employee
-$900,321
Market Cap
1.07B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 221 | 12 | 5.74% |
| Dec 31, 2024 | 209 | -271 | -56.46% |
| Dec 31, 2023 | 480 | -21 | -4.19% |
| Dec 31, 2022 | 501 | 38 | 8.21% |
| Dec 31, 2021 | 463 | 131 | 39.46% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| AbCellera Biologics | 562 |
| Xeris Biopharma Holdings | 435 |
| Pharming Group | 407 |
| KalVista Pharmaceuticals | 275 |
| Geron | 258 |
| EyePoint | 214 |
| MapLight Therapeutics | 133 |
| Septerna | 130 |
QURE News
- 5 days ago - UNIQURE DEADLINE APPROACHING: Bragar Eagel & Squire, P.C. Encourages uniQure N.V. - GlobeNewsWire
- 8 days ago - QURE SHAREHOLDER NOTICE: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of "Distorted" Data - PRNewsWire
- 4 weeks ago - This biotech's stock is soaring after a ‘polarizing' FDA official is stepping down - Market Watch
- 4 weeks ago - Federal health officials attacked an Amsterdam-based biotech company seeking approval of a Huntington's disease treatment and accused it of lying - WSJ
- 4 weeks ago - FDA official calls UniQure's gene therapy a 'failed' treatment for Huntington's disease - CNBC
- 4 weeks ago - Sr. FDA official calls Uniqure's Huntington's disease treatment a failure - Reuters
- 4 weeks ago - FDA Defends Call For Placebo Study In uniQure Huntington's Gene Therapy Trial - Benzinga
- 4 weeks ago - FDA official says UniQure fell short on Huntington's trial, defends new study request - Reuters